Fairbanks Pharmaceuticals

Curing diabetes through beta cell repair and regeneration

Skip to content
  • Home
  • About Us
  • Latest News
  • Advisors
  • Contact Us

Fairbanks M2D2 Challenge Profile

March 28, 2018Company NewsMark Schneyer

Tonight is the Challenge Pitch-off for the  M2D2 $200K Challenge, and Fairbanks will be there competing as one of 20 finalists.

Check out the interview with CEO Alan Schneyer published on the M2D2 site today!

Post navigation

← Fairbanks Presents at Endocrine Society Annual Meeting The Science Behind the Fairbanks Therapeutic Strategy →

Our mission:  To develop new therapies for type 1 and type 2 diabetes

Fairbanks Pharmaceuticals is developing transformative diabetes therapies that address the underlying cause of diabetes.

Subscribe to Fairbanks Pharma Email Updates

Enter your email address to get occasional updates with our latest news.

Recent News

  • Newly Published Study Validates Fairbanks Approach
  • Fairbanks Research and Development Continues
  • New publication on TGFβ family of proteins in diabetes

Fairbanks on Twitter

My Tweets

Administrative Offices

158 Laurel St
Concord MA 01742

Research Laboratory

Baystate Research Facility 3601 Main St, 2nd Floor Springfield MA 01199

Proudly powered by WordPress